Get the latest crypto news, updates, and reports by subscribing to our free newsletter.
Giấy phép số 4978/GP-TTĐT do Sở Thông tin và Truyền thông Hà Nội cấp ngày 14 tháng 10 năm 2019 / Giấy phép SĐ, BS GP ICP số 2107/GP-TTĐT do Sở TTTT Hà Nội cấp ngày 13/7/2022.
© 2026 Index.vn
Immix Biopharma, Inc. (Nasdaq: IMMX) said it will participate in and host institutional investor meetings at the Jefferies Global Healthcare Conference taking place June 2-4, 2026, in New York, NY.
The company plans to be available for one-on-one meetings during the conference. Interested investors are instructed to contact their Jefferies representative to request meetings. A link to access a replay, when available, will be posted on the Immix website under the Investors section on the Presentation & Events page.
Immix Biopharma describes itself as the global leader in relapsed/refractory AL amyloidosis. The company’s lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201, which it says includes a “digital filter” designed to filter out non-specific activation.
Immix states that NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL amyloidosis, NEXICART-2 (NCT06097832), with a registrational design. The company also reports that NXC-201 has received Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) from the U.S. FDA, and Orphan Drug Designation (ODD) from the FDA and the European Medicines Agency (EMA).
Mike Moyer, LifeSci Advisors: mmoyer@lifesciadvisors.com
Company Contact: irteam@immixbio.com
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…